Translational Laboratory Shared Service

7.0摘要：转化型实验室共享服务 UMGCC的转化实验室共享服务(TLSS)产生了临床前(基于细胞和动物) 和临床数据，以支持前沿研究，并为Grant提供初步数据 I/II期临床试验的提交和意向书，这是TLSS活动的主要推动力。TLSS计划 还开发了体外和体内临床前模型，用于评估要翻译的新型抗癌药物 将科学理念转化为治疗学。TLSS支持UMGCC的许多I/II期临床试验 生物标本以及开发和执行相关研究的化验，以支持这些试验。这个 TLSS的独特之处在于它提供了通常不由任何一个核心提供的服务和资源的组合， 主要支持从事临床和转化性研究和临床前研究的医生 进行临床前活体研究的研究人员、研究员和学生。 TLSS支持I/II期临床试验，提供体内肿瘤模型，产生初步的 用于授权申请的数据，支持专利申请的提交，并生成提供 新的临床试验方案的基础。这些努力的结果是出版了包括TLSS工作人员的出版物 清楚地表明了TLSS对UMGCC癌症研究的积极影响。自.以来 自2010年以来，TLSS已为27项临床试验提供了支持，包括为4项新的 研究人员发起的试验；通过伞状动物方案进行了200多项动物实验 简化研究人员获取动物研究的途径；并向8个同行审查、资助的机构提供初步数据 批准申请。 2014年，TLSS支持了46名癌症中心成员，涵盖了所有5个研究项目(占所有研究项目的18% UMGCC成员)，其中63%拥有同行审查的资金。TLSS支持许多与癌症相关的 每年发表论文，其中许多发表在影响较大的期刊上，包括《自然通讯》和《临床癌症》 研究。

7.0 Abstract: Translational Laboratory Shared Service The Translational Laboratory Shared Service (TLSS) at UMGCC generates preclinical (cell- and animal-based) and clinical data for investigators to support cutting-edge research and provides preliminary data for grant submissions and letters of intent for Phase I/II clinical trials, which is a major thrust of TLSS activity. The TLSS also develops in vitro and in vivo preclinical models for evaluation of novel anticancer agents to translate scientific ideas into therapeutics. The TLSS supports many Phase I/II clinical trials at UMGCC by isolating biological specimens and developing and executing assays for correlative studies to support these trials. The TLSS is unique in that it provides a combination of services and resources usually not offered by any one core, predominantly supporting physicians engaged in clinical and translational research and preclinical investigators, fellows, and students conducting preclinical in vivo studies. The TLSS supports Phase I/II clinical trials, provides access to in vivo tumor models, generates preliminary data for grant applications, supports submission of patent applications, and generates data that provide the basis for new clinical trial protocols. These efforts have resulted in publications that include TLSS staff as coauthors, clearly demonstrating the positive impact the TLSS has on cancer research at UMGCC. Since 2010, the TLSS has provided support for 27 clinical trials, including providing preliminary data for 4 new investigator-initiated trials; carried out over 200 animal experiments through an umbrella animal protocol that streamlines investigators’ access to animal studies; and provided preliminary data to 8 peer-reviewed, funded grant applications. In 2014, the TLSS supported 46 Cancer Center members spanning all 5 research programs (18 percent of all UMGCC members), 63 percent of whom have peer-reviewed funding. The TLSS supports many cancer-related publications annually, many in high-impact journals including Nature Communications and Clinical Cancer Research.